NEWS DETAIL

  • Source : Press Release
  • Date : 2017-06-15

Veralox Therapeutics Is Awarded a $319,133 Small Business Innovative ResearchGrant (SBIR) from the National Institutes of Health (NIH)

Veralox Therapeutics is awardeda $319,133 Small Business Innovative ResearchGrant (SBIR) from the National Institutes of Health (NIH) to develop a novel therapeutic for patients suffering from heparin-induced thrombocytopenia and thrombosis (HIT/HITT); a designated orphan disease that impacts some 20,000 patients annually, has a high mortality rate and often result in limb amputations.